PHP
ABOS icon

Parkman Healthcare Partners’s Acumen Pharmaceuticals ABOS Stock Holding History

Parkman Healthcare Partners’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-576,657
Closed -$2.34M – 91
2024
Q1 		$2.34M Sell
576,657
-26,840
-4% -$101K 0.29% 82
2023
Q4 		$2.32M Buy
603,497
+103,683
+21% +$308K 0.33% 71
2023
Q3 		$2.07M Buy
+499,814
New +$3.09M 0.38% 70

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Parkman Healthcare Partners's ABOS Position: Q2 2024 in Review

Parkman Healthcare Partners sold out of Acumen Pharmaceuticals (ABOS) in Q2 2024, closing a stake of 576,657 shares — an estimated $2.34M sold.

Parkman Healthcare Partners first reported a position in ABOS in Q3 2023 and held it in 3 quarters. The position peaked at $2.34M in Q1 2024. 81 funds tracked by Wall St. Rank hold ABOS as of Q2 2024.

  • Parkman Healthcare Partners reported no remaining Acumen Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 576,657 Acumen Pharmaceuticals shares in Q2 2024, an estimated $2.34M.
  • Parkman Healthcare Partners first reported a position in Acumen Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Parkman Healthcare Partners's Acumen Pharmaceuticals position peaked at $2.34M in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2024.

Based on Parkman Healthcare Partners's 13F filing for Q2 2024, filed 14 Aug 2024.